Lipoprotein(a) and Benefit of PCSK9 Inhibition in Emergency Complex Higher-risk and Indicated Patients

被引：0
|
作者：
Zhi-li Jin
Tao He
Li Peng
Xiao-yan Wu
Di Fan
Ming Chen
Yong-zhen Fan
Yuan-lin Guo
Zhi-bing Lu
Hai-rong Wang
机构：
[1] Zhongnan Hospital of Wuhan University,Department of Cardiovascular Medicine
[2] Wuhan University,Institute of Myocardial Injury and Repair
[3] Chinese Academy of Medical Sciences & Peking Union Medical College,Cardio
来源：
Current Medical Science | 2023年 / 43卷
关键词：
PCSK9 inhibitor; complex higher-risk and indicated patients; lipoprotein(a) level; low-density lipoprotein cholesterol level; 2-year cardiovascular event rate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1206 / 1212
页数：6
相关论文
共 50 条
  • [21] Lipid control in patients at high cardiovascular risk: focus on PCSK9 inhibition
    Filardi, Pasquale Perrone
    Paolillo, Stefania
    Trimarco, Bruno
    GIORNALE ITALIANO DI CARDIOLOGIA, 2015, 16 (01) : 44 - 51
  • [22] PCSK9 inhibition reduces cardiovascular events in high-risk patients
    Karina Huynh
    Nature Reviews Cardiology, 2017, 14 : 251 - 251
  • [23] Feasibility and safety of excimer laser coronary atherectomy in complex higher-risk/and indicated patients
    马玉良
    ChinaMedicalAbstracts(InternalMedicine), 2019, 36 (03) : 159 - 160
  • [24] PCSK9 inhibition, LDL and lipopolysaccharides: a complex and "dangerous" relationship
    Femino, Raimondo
    Femino, Giovanni
    Cavezzi, Attilio
    Troiani, Emidio
    INTERNATIONAL ANGIOLOGY, 2021, 40 (03) : 248 - 260
  • [25] PCSK9 Inhibition: New Treatment Options and Perspectives to Lower Atherogenic Lipoprotein Particles and Cardiovascular Risk
    Julia Brandts
    Dirk Müller-Wieland
    Current Atherosclerosis Reports, 2019, 21
  • [26] PCSK9 Inhibition: New Treatment Options and Perspectives to Lower Atherogenic Lipoprotein Particles and Cardiovascular Risk
    Brandts, Julia
    Mueller-Wieland, Dirk
    CURRENT ATHEROSCLEROSIS REPORTS, 2019, 21 (10)
  • [27] PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
    Carugo, Stefano
    Sirtori, Cesare R.
    Corsini, Alberto
    Tokgozoglu, Lale
    Ruscica, Massimiliano
    CURRENT ATHEROSCLEROSIS REPORTS, 2022, 24 (12) : 995 - 1004
  • [28] PCSK9 Inhibition and Risk of Diabetes: Should We Worry?
    Stefano Carugo
    Cesare R. Sirtori
    Alberto Corsini
    Lale Tokgozoglu
    Massimiliano Ruscica
    Current Atherosclerosis Reports, 2022, 24 : 995 - 1004
  • [29] PCSK9 Inhibition to Reduce Cardiovascular Risk Tempering Expectations
    Waters, David D.
    Hsue, Priscilla Y.
    CIRCULATION RESEARCH, 2017, 120 (10) : 1537 - 1539
  • [30] Inhibition of PCSK9: is this the way forward for managing residual risk?
    Chowdhury, Sharmistha Roy
    Rees, Alan
    CURRENT OPINION IN LIPIDOLOGY, 2012, 23 (05) : 509 - 510
12345